Aligos Therapeutics (NASDAQ:ALGS) Receives Buy Rating from HC Wainwright

Aligos Therapeutics (NASDAQ:ALGS)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $50.00 price objective on the stock.

A number of other research analysts have also recently commented on ALGS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Wednesday, January 21st. UBS Group initiated coverage on Aligos Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $20.00 price target for the company. Finally, Wall Street Zen cut Aligos Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $35.00.

Aligos Therapeutics Price Performance

Shares of Aligos Therapeutics stock traded up $0.29 during trading on Wednesday, hitting $7.39. The stock had a trading volume of 31,264 shares, compared to its average volume of 59,579. Aligos Therapeutics has a 12 month low of $3.76 and a 12 month high of $13.69. The firm’s fifty day simple moving average is $7.79 and its 200-day simple moving average is $9.03. The stock has a market cap of $45.42 million, a PE ratio of -0.86 and a beta of 2.67.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($1.91) EPS for the quarter, beating the consensus estimate of ($2.09) by $0.18. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 28.16%. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.27 million. Analysts expect that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aligos Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. NorthCrest Asset Manangement LLC purchased a new position in shares of Aligos Therapeutics during the third quarter worth approximately $98,000. Susquehanna International Group LLP bought a new stake in shares of Aligos Therapeutics during the third quarter valued at approximately $99,000. HRT Financial LP purchased a new stake in shares of Aligos Therapeutics in the fourth quarter valued at approximately $106,000. DRW Securities LLC bought a new position in Aligos Therapeutics in the fourth quarter worth approximately $111,000. Finally, XTX Topco Ltd bought a new position in Aligos Therapeutics in the second quarter worth approximately $100,000. 60.43% of the stock is currently owned by institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.